| http://www.w3.org/ns/prov#value | - a result, this cancer can be very difficult to treat; it does not respond to therapies that target estrogen and progesterone receptors, such as tamoxifen (Nolvadex), fulvestrant (Faslodex) and aromatase inhibitors (Femara, Arimidex and Aromasin), or to HER2-targeted therapies such as trastuzumab (Herceptin) and lapatinib (Tykerb).About 15 to 20 percent of breast cancers are triple-negative.
|
